Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

PharmaCyte Biotech, Inc. Common Stock

PMCB

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

Last trade $5.51
Day change -$0.06 (-1.08%)
Day range $5.53 – $6.04
Volume 4,564
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.15M
Price / earnings
—
Price / book
0.11×
Price / sales
—
EV / sales
—
EV / EBITDA
1.65×

Profitability

Earnings per share
-$63.57
Return on assets
-97.84%
Return on equity
-130.58%
Dividend yield
10.47%

Liquidity and leverage

Debt / equity
0×
Current ratio
40.3×
Quick ratio
40.3×
Cash ratio
23.08×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PMCB, quarterly periods
Line itemQ1 FY2027 Jul 31, 2026Q4 FY2026 Apr 30, 2026Q3 FY2026 Jan 31, 2026Q2 FY2026 Oct 31, 2025Q1 FY2026 Jul 31, 2025Q4 FY2025 Apr 30, 2025Q3 FY2025 Jan 31, 2025Q2 FY2025 Oct 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$946.71K$4.07M$2.02M$1.23M$753.15K$915.13K$4.01M$1.01M
Research and development$60K$273.11K$93.11K$141.09K$95.16K$126.73K$329.36K$97.47K
Total operating expenses$1.01M$5.89M$2.12M$1.38M$848.31K$1.04M$4.34M$1.11M
Operating income-$1.01M-$5.89M-$2.12M-$1.38M-$848.31K-$1.04M-$4.34M-$1.11M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.08M-$16.38M$746.86K-$7.42M-$8.36M$11.75M-$15.03M-$1.47M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.08M-$16.38M$746.86K-$7.42M-$8.36M$11.75M-$15.03M-$1.47M
Net income attributable to common shareholders-$5.79M-$20.16M-$1.56M-$8.42M-$8.36M$10.85M-$18.33M-$2.96M
EBITDA-$1.01M-$4.34M-$2.12M-$1.38M-$848.31K-$1.04M-$4.34M-$1.11M
Basic earnings per share-$10.26-$1.89-$3.23-$23.56-$23.37$1.75-$45.79-$7.41
Diluted earnings per share-$10.26-$1.89-$3.23-$23.56-$23.37$1.75-$45.79-$7.41

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider

The pancreatic cancer treatment market is expected to grow significantly, driven by the increasing prevalence of the disease and the development of innovative therapies. Factors like the rising geriatric population, emerging chemotherapies, and increased healthcare investments in Asia-Pacific and the Middle East are further propelling the market growth.

Seeking Alpha

Wall Street Breakfast: What Moved Markets

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (NASDAQ: ADGI) (IPOed Aug. 6) Alkermes plc (NASDAQ: ALKS) Bio-Rad Laboratories, Inc. (NYSE: BIO) Candel Therapeutics, Inc. (NASDAQ: CADL) (IPOed July 26) Century Therapeutics, Inc. (NASDAQ: IPSC) (reacted to its second-quarter results) Dynavax Technologies Corporation (NASDAQ: DVAX) Gilead Sciences, Inc. (NASDAQ: GILD) Harvard Bioscience, Inc. (NASDAQ: HBIO) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Innoviva, Inc. (NASDAQ: INVA) Johnson & Johnson (NYSE: JNJ) Sesen Bio, Inc. (NASDAQ: SESN) Tenaya Therapeutics, Inc. (NASDAQ: TNYA) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 12) ABVC BioPharma, Inc. (NASDAQ: ABVC) (announced its second-quarter results) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Achilles Therapeutics plc (NASDAQ: ACHL) Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) Akero Therapeutics, Inc. (NASDAQ: AKRO) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Alzamend Neuro, Inc. (NASDAQ: ALZN) Aprea Therapeutics, Inc. (NASDAQ: APRE) (announced that FDA imposed clinical hold on lymphoid malignancy study) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) (announced second-quarter results) Atai Life Sciences N.V. (NASDAQ: ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ: AXSM) Aytu Biopharma, Inc. (NASDAQ: AYTU) Baudax Bio, Inc. (NASDAQ: BXRX) Baxter International Inc. (NYSE: BAX) Biodesix, Inc. (NASDAQ: BDSX) Biomea Fusion, Inc. (NASDAQ: BMEA) Cellectar Biosciences, Inc. (NASDAQ: CLRB) Celularity Inc. (NASDAQ: CELU) Codex DNA, Inc. (NASDAQ: DNAY) CytomX Therapeutics, Inc. (NASDAQ: CTMX) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (reacted to its second-quarter results) Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Ensysce Biosciences, Inc. (NASDAQ: ENSC) Epizyme, Inc. (NASDAQ: EPZM) Exicure, Inc. (NASDAQ: XCUR) (announced its second-quarter results) EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) FibroGen, Inc. (NASDAQ: FGEN) Flexion Therapeutics, Inc. (NASDAQ: FLXN) Grifols, S.A. (NASDAQ: GRFS) Heron Therapeutics, Inc. (NASDAQ: HRTX) HOOKIPA Pharma Inc. (NASDAQ: HOOK) (reacted to its second-quarter result) Hoth Therapeutics, Inc. (NASDAQ: HOTH) IMARA Inc. (NASDAQ: IMRA) IN8bio, Inc. (NASDAQ: INAB) Incyte Corporation (NASDAQ: INCY) Inhibikase Therapeutics, Inc. (NASDAQ: IKT) iRhythm Technologies, Inc. (NASDAQ: IRTC) Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Kronos Bio, Inc. (NASDAQ: KRON) Lava Therapeutics B.V. (NASDAQ: LVTX) Liminal BioSciences Inc. (NASDAQ: LMNL) Lumos Pharma, Inc. (NASDAQ: LUMO) MediciNova, Inc. (NASDAQ: MNOV) Moleculin Biotech, Inc. (NASDAQ: MBRX) (reacted to its second-quarter ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 13, 20261-for-19reverse split
Jul 12, 20211-for-1,500reverse split
Dec 8, 20033-for-1forward split